Hanson R N
Department of Chemistry, Northeastern University, Boston, MA 02115, USA.
Curr Pharm Des. 2000 Sep;6(14):1457-68. doi: 10.2174/1381612003399211.
Targeted radiotherapy using Auger electron-emitting pharmaceuticals offers both advantages and challenges compared to alternative alpha - or beta -emitting agents. The low energy Auger electrons deposit their energy within the target cell thereby minimizing collateral damage. To achieve this effect, however, the radiopharmaceutical must incorporate the appropriate radionuclide, be efficiently synthesized, and once administered, be distributed selectively to its biological target. This review covers the synthesis of agents which have prepared over the past decade either as Auger electron-emitting radiopharmaceuticals or which have the potential as such. While not an exhaustive review, the major classes of agents, such as hormone receptor ligands, nucleoside analogs and intercalating agents are described.
与其他发射α或β粒子的药剂相比,使用发射俄歇电子的药物进行靶向放射治疗既有优势也有挑战。低能俄歇电子在靶细胞内沉积能量,从而将附带损伤降至最低。然而,为了实现这一效果,放射性药物必须包含合适的放射性核素,要高效合成,并且一旦给药,要选择性地分布到其生物靶点。本综述涵盖了在过去十年中制备的作为发射俄歇电子的放射性药物或具有此类潜力的药剂的合成。虽然并非详尽无遗的综述,但描述了主要类型的药剂,如激素受体配体、核苷类似物和嵌入剂。